Study validates effectiveness of Vapotherm’s neonatal technology

Prototype shown to maintain target range of saturation levels better than manual controls


Published:

A new study validates the effectiveness of a new product from Exeter-based respiratory technologies manufacturer, Vapotherm. IntellO2 is an automated oxygen controller module prototype developed by the global medical technology firm that helps clinicians maintain a physician-prescribed oxygen saturation range for newborns.

The results of study were published by Reynolds and colleagues in the Archives of Disease in Childhood: Fetal and Neonatal Edition, entitled “Randomised crossover study of automated oxygen control for preterm infants receiving nasal High Flow.” The data show that trained staff were able to keep the babies’ oxygen saturation in the target range 49 percent of the time with manual controls alone. When using the IntellO2 module staff was able to maintain the babies in range 80 percent of the time.

“We are very pleased with these results. This study shows the ability of the IntellO2 to help clinicians maintain premature babies in the prescribed target pulse oxygenation range. We now have strong evidence that when compared to manual control, using the IntellO2 improves the ability to keep babies within target saturation range,” said Joe Army, CEO of Vapotherm. “We are excited to continue development of this unique technology to help clinicians control oxygenation, since both too much and too little oxygen have important clinical consequences. We see applications for this technology initially in the neonate patient population, and eventually for oxygen vulnerable adult patients as well.”

The IntellO2 works with the Precision Flow system, using pulse oximetry to monitor blood oxygen saturation and adjust inspired oxygen concentration settings accordingly. It utilizes a unique proprietary software algorithm designed to work with Precision Flow​ Hi-VNI Technology. 

The IntellO2 system is currently not commercially available, though the FDA recently approved Vapotherm's Precision Flow Hi-VNI system, which assists patients who have respiratory distress.

Edit ModuleShow Tags
Edit ModuleShow Tags